Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer

Completed · Phase 1/Phase 2

Conditions studied: Small-cell Lung Cancer

In brief

The main purpose of this Phase 1/2 study is to determine the safety and efficacy of pegzilarginase in combination with pembrolizumab in patients with ED-SCLC who have relapsed or progressive disease on or within 6 months of platinum-based chemotherapy.

Key facts

Study ID
NCT03371979
Run by
Aeglea Biotherapeutics
People needed
68
Starts
2017-12-21
Expected to finish
2021-01-01
Last updated by the study team
2021-11-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.